Paragon Advisors’s 10x Genomics TXG Stock Holding History

Paragon Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9,315	Closed	-$1.39M	–	85
2021 Q4	$1.39M	Sell	9,315 -5,669	-38%	-$868K	0.68%	40
2021 Q3	$2.18M	Buy	14,984 +2,813	+23%	+$483K	1.06%	30
2021 Q2	$2.38M	Buy	12,171 +4,200	+53%	+$760K	1.12%	26
2021 Q1	$1.44M	Buy	7,971 +800	+11%	+$138K	0.79%	31
2020 Q4	$1.01M	Sell	7,171 -85	-1%	-$12.3K	0.54%	53
2020 Q3	$905K	Buy	7,256 +895	+14%	+$93.9K	0.6%	51
2020 Q2	$568K	Buy	+6,361	New	+$495K	0.46%	71

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paragon Advisors's TXG Position: Q1 2022 in Review

Paragon Advisors sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 9,315 shares — an estimated $1.39M sold.

Paragon Advisors first reported a position in TXG in Q2 2020 and held it in 7 quarters. The position peaked at $2.38M in Q2 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

Paragon Advisors reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
Paragon Advisors sold 9,315 10x Genomics shares in Q1 2022, an estimated $1.39M.
Paragon Advisors first reported a position in 10x Genomics in Q2 2020 and held it in 7 quarters.
Paragon Advisors's 10x Genomics position peaked at $2.38M in Q2 2021.
314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Paragon Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.